The Choice of Administration Options

Talk to your patients about the most convenient option for them

Image: BENLYSTA SC Autoinjector

BENLYSTA AUTOINJECTOR

At home

BENLYSTA Autoinjector and prefilled syringe are approved for subcutaneous (SC) use in patients 18 years and older.

Image: BENLYSTA IV

BENLYSTA IV

In-office

BENLYSTA for intravenous (IV) is approved for infusion only in patients with SLE 5 years and older and patients with lupus nephritis 18 years and older.

BENLYSTA Autoinjector for SC use

Icon: Subcutaneous Administration of BENLYSTA

200 mg/mL single-dose prefilled Autoinjector

Once weekly dosing with at-home convenience

Icon: Calendar With Weekly Check Marks

BENLYSTA Autoinjector dosing for SLE

Image: BENLYSTA SC Autoinjector

BENLYSTA Autoinjector dosing for active lupus nephritis

Image: BENLYSTA SC Autoinjector

* The 400-mg dose requires administration of 2 autoinjectors (2 x 200 mg). The dose is given via subcutaneous injection in the abdomen or thigh. When the 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.

 

ARE YOU READY TO PRESCRIBE BENLYSTA
TO YOUR PATIENTS WITH LUPUS NEPHRITIS?

ARE YOU READY TO PRESCRIBE
BENLYSTA TO YOUR PATIENTS
WITH LUPUS NEPHRITIS?

Image: BENLYSTA Autoinjector 200 mg/ml written prescription

INSTRUCTIONS FOR USE:

Icon: Subcutaneous Administration of BENLYSTA

Autoinjector

Icon: 1-4 Weeks

Transitioning from IV therapy to SC administration

Image: BENLYSTA IV to BENLYSTA SC
Image: BENLYSTA IV to BENLYSTA SC

Patients with SLE: Administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. IV and SC are not to be used concurrently.

Patients with LN: Transition to subcutaneous therapy can be done any time after the patient completes the first 2 intravenous doses. Administer the first subcutaneous dose 1 to 2 weeks after the last intravenous dose. IV and SC are not to be used concurrently.

  • Administration Instructions for BENLYSTA for SC Use

    • It is recommended that the first subcutaneous injection of BENLYSTA should be under the supervision of a healthcare professional. The healthcare provider should provide proper training in subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions. A patient may self-inject or the patient caregiver may administer BENLYSTA subcutaneously after the healthcare provider determines it is appropriate.
    • Instruct the patient or patient caregiver to follow the directions for administration provided in the Instructions for Use.
    • Instruct the patient to remove the Autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes prior to the subcutaneous injection. Do not warm BENLYSTA in any other way.
    • Prior to administration, instruct the patient or patient caregiver to visually inspect the window of the Autoinjector or the prefilled syringe for particulate matter or discoloration. BENLYSTA should be clear to opalescent and colorless to pale yellow. Do not use BENLYSTA if the product exhibits discoloration or particulate matter. Instruct the patient not to use the BENLYSTA Autoinjector or prefilled syringe if dropped on a hard surface.
    • When injecting in the same body region, advise the patient to use a different injection site for each injection; never give injections into areas where the skin is tender, bruised, red, or hard. When a 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.
    • Instruct the patient to administer BENLYSTA 200 mg once a week, preferably on the same day each week.

    If a dose is missed, instruct the patient to administer a dose as soon as the patient remembers. Thereafter, the patient can resume dosing on their usual day of administration or start a new weekly schedule from the day that the missed dose was administered.

Did you know?

Icon: 76 percent

76% of patients with SLE taking BENLYSTA preferred administration with the Autoinjector over IV infusion1,2*

* A follow-up survey was conducted in patients with SLE (N=43) who completed open-label, multi-dose, usability, tolerability, and safety study of subcutaneous (SC) belimumab where they were switched from IV or prefilled syringe belimumab to self-administered doses using the Autoinjector for 8 weekly doses. Patients (n=42) were asked, “What is your preference for receiving BENLYSTA: using the Autoinjector or IV?”

BENLYSTA IV

Icon: Intravenous Administration of BENLYSTA

10 mg/kg intravenous infusion (in-office)

Scheduling first 3 doses in advance may be helpful for patients

Icon: Calendar

BENLYSTA IV is administered as a 1-hour infusion

10 mg/kg administered every 2 weeks for the first 3 doses and every 4 weeks thereafter

BENLYSTA IV is supplied as:

120 mg in a 5-mL single-dose vial
400 mg in a 20-mL single-dose vial

Dosing schedule for SLE and LN

Consider scheduling the first 3 doses in advance to start your patients off right.

Image: Dosing Schedule for SLE and LN

  • Find out more about the BENLYSTA IV infusion process

    ADMINISTRATION INSTRUCTIONS

    • The diluted solution of BENLYSTA should be administered by intravenous infusion over a period of 1 hour.
    • BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis.
    • BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.
    • Do not administer as an intravenous push or bolus.

BENLYSTA PREFILLED GLASS SYRINGE FOR SC USE

Icon: Pre-Filled Syringe

Instructions for use (at home):

200 mg/mL single-dose prefilled glass syringe

Icon: Calendar With Weekly Check Marks

BENLYSTA Prefilled Syringe SC dosing for SLE

Image: Prefilled Syringe SC Dosing for SLE

BENLYSTA Prefilled Syringe SC dosing for active lupus nephritis

Image: Prefilled Syringe SC Dosing for for Active Lupus Nephritis

* The 400-mg dose requires administration of 2 prefilled syringes (2 x 200 mg). The dose is given via subcutaneous injection in the abdomen or thigh. When the 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.

Useful Tools

Icon: Intravenous Administration of BENLYSTA

Find the vial combination that helps minimize product waste.

Vial Calculator

Icon: Calendar

Calculate patients’ infusion dates.

Infusion Scheduler

Additional Resources

Starting a Patient on BENLYSTA Important downloads to help your patients as they get started with BENLYSTA.

Access & Support Learn more about how to access BENLYSTA and enroll patients in the BENLYSTA Cares Program.

Talk to your patients about the dosing option they prefer

Banner Image: BENLYSTA Dosing Options
Banner Image: BENLYSTA Dosing Options
Banner Image: BENLYSTA Dosing Options